MedTrace Logo

Dissection of the Superior Mesenteric Artery

NCT05171842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2025-12-04

No results posted yet for this study

Summary

This study aims to evaluate the prognosis of patients with spontaneous solitary dissection of superior mesenteric artery (SIDSMA) who have been treated with stents.

Conditions

  • Dissection of the Superior Mesenteric Artery

Interventions

BEHAVIORAL

Observe the prognosis after stent implantation

Observe the prognosis of patients after undergoing specific operations. Specific surgery: Use femoral artery or brachial artery to implant bare stent (stent with diameter ≤7mm is suggested to use thin-wall stent, stents with \>7mm are not restricted) to restore the blood flow of the true lumen superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulant therapy should be performed for at least 1 day after surgery. Anticoagulant drugs are not restricted. After discharge from the hospital, the dual anti-platelet drugs should be taken for 3 months, and a single anti-platelet drug should be maintained for at least 1 year.

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Affiliated Hospital of Jiaxing University

    collaborator OTHER

  • People's Hospital of Dangyang

    collaborator OTHER

  • First People's Hospital of Hangzhou

    collaborator OTHER

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Hongkun zhang · First Affiliated Hospital of Zhejiang University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171842 on ClinicalTrials.gov